../assets/websitedata/webcast.gw-pharma.com/Files/webcast4.mp4
Epilepsy Focus Webcast: sharing experience with Epidyolex® (cannabidiol) Wednesday 23 September 2020
All
0
>
Welcome and introduction
289
Initiating patients with GW CBD (case studies)
1242
Initiating patients with GW CBD (discussion)
1540
Managing adverse events (case studies)
1993
Managing adverse events (discussion)
2365
Determining the optimal dose of GW CBD (case studies)
3130
Determining the optimal dose of GW CBD (discussion)
3379
Initiating GW CBD in patients who have previously received non-regulatory approved cannabis-based products (case studies)
3790
Initiating GW CBD in patients who have previously received non-regulatory approved cannabis-based products (discussion)
4030
Panel discussion: Early versus late intervention with GW CBD
4560
Summary and close